#China #Minghui #Qilu #MHB088C #Hangzhou, Shanghai

Update on MHB088C for mCRPC at ASCO 2026

Minghui Pharmaceutical, a company dedicated to the development of novel therapies in oncology, has recently shared significant results from their continuing studies on MHB088C (also known as QLC5508) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This promising investigational drug is focused on treating patients with metastatic castration-resistant prostate cancer (mCRPC), a daunting condition characterized by limited treatment options.

Clinical Trial Overview

MHB088C is currently undergoing evaluation in a Phase I/II clinical trial that specifically targets heavily pretreated patients suffering from mCRPC. These patients often have undergone multiple lines of therapy, including androgen receptor pathway inhibitors and taxane-based chemotherapy. According to the latest data, the study enrolled 59 participants as of the cutoff date of November 30, 2025, many of whom had a history of aggressive prior treatments. For instance:

• - Approximately 74.6% of responders had received three or more previous therapeutic lines.
• - A staggering 84.7% had been exposed to taxanes, a common chemotherapy class.
• - 28.8% of the patients had undergone three or more treatment lines with second-generation ARPIs.
• - Moreover, 16.9% reported having experienced two or more lines of taxane therapy.

Promising Results

The clinical results shared during the ASCO meeting showcased the robust anti-tumor activity associated with MHB088C. The median radiographic progression-free survival (rPFS) rate has not yet been reached, indicating a promising therapeutic profile. Notably, a 12-month rPFS rate was documented at 71.7% (95% CI, 52.6%-84.3%). Particularly, patients treated with the optimal dose of 2.0 mg/kg showed an even higher 12-month rPFS rate of 78.6% (95% CI, 50.7%-91.8%). These statistics underscore the drug's potential for prolonging disease control in this difficult-to-treat patient population.

Safety and Tolerability

In discussions around safety, MHB088C demonstrated a favorable safety profile that aligns with previous findings. The most frequently reported treatment-emergent adverse events (TEAEs) were manageable. The adverse effects observed in more than 20% of patients included:

• - Decreased neutrophil count: 25.4%
• - Anemia: 23.7%
• - Decreased white blood cell count: 20.3%

The management of these effects is crucial for the continued development of MHB088C, particularly for mCRPC patients who often experience significant treatment challenges.

Expert Commentary

Dr. Guoqing Cao, CEO of Minghui Pharmaceutical, expressed enthusiasm about these findings, stating, "These updated data presented at ASCO further reinforce the potential of MHB088C as a differentiated therapeutic option for patients with metastatic castration-resistant prostate cancer, particularly those with limited treatment alternatives after multiple prior therapies."

His comments emphasize the importance of advancing MHB088C as a viable option addressing significant unmet medical needs within oncology. Minghui Pharmaceutical aims to progress further with MHB088C as they explore additional studies and potential indications in cancer treatment.

Ongoing and Future Studies

Under a collaboration agreement, Qilu Pharmaceutical maintains exclusive rights to continue the drug's development within Greater China. This partnership is actively pursuing clinical evaluations across numerous indications for MHB088C. Additionally, the program has received several Breakthrough Therapy Designations, unveiling continuous hope for its prospects in treating mCRPC and beyond.

Minghui's pipeline includes a substantial range of innovative treatments, spotlighting both research flexibility and commitment to combating unmet needs in oncology. Moving forward, the company looks ahead to refining its strategies for MHB088C, including combining it with other novel investigational agents like MHB039A—a promising PD-1/VEGF bispecific antibody.

In conclusion, the momentum surrounding MHB088C engenders optimism for its role in the evolving landscape of cancer therapeutics. As clinical trials proceed, updates will continue to shape our understanding of its full potential impact in treating advanced prostate cancers.